Mechanism Overview: Concentrating the Body’s Growth Factors
Platelet-rich plasma (PRP) is an autologous preparation of concentrated platelets in a small volume of plasma, obtained by centrifuging the patient’s own blood. Platelets are rich in alpha granules that contain over 30 growth factors and cytokines, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), vascular endothelial growth factor (VEGF), insulin-like growth factor 1 (IGF-1), fibroblast growth factor (FGF), and epidermal growth factor (EGF). When PRP is injected into the scalp and the platelets are activated (by calcium chloride or thrombin), these growth factors are released in high concentrations, creating a pro-regenerative microenvironment around the hair follicle. PRP’s appeal lies in its autologous nature (no risk of immune rejection or disease transmission) and its multi-growth-factor approach, which addresses several pathways simultaneously.
The PRP hair treatment market has grown rapidly, with costs typically ranging from $500-1,500 per session and a recommended course of 3-6 sessions. However, the clinical evidence is more nuanced than enthusiastic clinic marketing suggests, and significant variability in PRP preparation methods makes it difficult to compare results across studies.
Detailed Mechanism: Key Growth Factors in PRP
PDGF (Platelet-Derived Growth Factor) is the most abundant growth factor in platelet alpha granules and exists as three isoforms: PDGF-AA, PDGF-BB, and PDGF-AB. PDGF binds to PDGF receptors (PDGFRα and PDGFRβ) on dermal papilla cells, activating the PI3K/Akt and Ras/MAPK pathways that promote cell proliferation and survival. A study by Li et al. (2012) demonstrated that PDGF-BB stimulates dermal papilla cell proliferation and upregulates VEGF expression, suggesting that PDGF’s effect on hair growth is partly mediated through enhanced vascularization.
VEGF (Vascular Endothelial Growth Factor) is released from platelets in concentrations approximately 3-5 times higher than in whole blood. As discussed in our dedicated article on VEGF, this growth factor drives perifollicular angiogenesis, expanding the capillary network that supplies the growing follicle. PRP-derived VEGF may be particularly important for improving the microcirculation of miniaturized follicles that have impaired vascular support.
IGF-1 (Insulin-Like Growth Factor 1) promotes matrix keratinocyte proliferation through PI3K/Akt signaling and delays catagen entry by suppressing TGF-β1. The IGF-1 in PRP may directly stimulate follicle cell proliferation and extend anagen duration. A study by Kwon et al. (2015) demonstrated that PRP increased IGF-1 expression in dermal papilla cells and promoted anagen re-entry in telogen follicles.
TGF-β1 has a dual role: at low concentrations, it promotes extracellular matrix synthesis and wound healing; at high concentrations, it promotes catagen and fibrosis. The TGF-β1 in PRP may contribute to the remodeling of the perifollicular matrix, but excessive TGF-β1 could theoretically be counterproductive. This balance may explain some of the variability in PRP results across studies and preparation methods.
Detailed Mechanism: PRP Preparation Variables
The composition of PRP—and thus its clinical effect—depends on several preparation variables. Platelet concentration: Most protocols aim for a 3-5 fold increase over baseline platelet count, but some systems produce 8-10 fold concentrations. Higher is not always better—excessively high platelet concentrations may create an unfavorable ratio of growth factors or trigger inflammatory responses.
Leukocyte content: PRP can be classified as leukocyte-poor (LP-PRP) or leukocyte-rich (LR-PRP). LR-PRP contains white blood cells that release additional cytokines and enzymes, including pro-inflammatory cytokines (IL-1β, TNF-α) that could theoretically counteract the anagen-promoting effects of growth factors. A study by Anastassopoulos et al. (2012) suggested that LP-PRP may be preferable for hair applications, but direct comparisons are limited.
Activation method: PRP can be activated ex vivo (with calcium chloride or thrombin before injection) or allowed to activate in vivo (by contact with tissue collagen). Ex vivo activation provides more controlled growth factor release, while in vivo activation may provide slower, more sustained release. The optimal activation method for hair growth is unknown.
Research Evidence: Clinical Trials
The most rigorous study is a randomized, placebo-controlled trial by Gentile et al. (2015), published in Stem Cells International. This study compared PRP injections to placebo (saline) in 20 patients with AGA over 3 months (3 sessions at 0, 1, and 2 months). The PRP group showed a statistically significant increase in hair density (mean +27 hairs/cm²) and hair diameter compared to placebo. Histological examination confirmed increased epidermal thickness, increased number of hair follicles, and increased VEGF expression in PRP-treated scalp.
A larger RCT by Puig et al. (2020), published in the Journal of the American Academy of Dermatology, examined PRP in 26 patients with female pattern hair loss over 6 months. The PRP group showed improvement in hair density and hair shaft diameter compared to placebo, but the effect size was modest and some patients did not respond. The authors noted that younger patients and those with earlier-stage hair loss responded better.
A meta-analysis by Gupta & Carviel (2016) analyzed 6 studies and concluded that PRP showed positive results for hair growth, but noted significant heterogeneity in preparation methods, injection protocols, and outcome measures. The authors called for standardized protocols and larger, well-designed RCTs.
Limitations and Practical Considerations
The most significant limitation is the lack of standardized preparation protocols. Different PRP systems (Arthrex, Magellan, EmCyte, etc.) produce PRP with different platelet concentrations, leukocyte content, and growth factor profiles, making it impossible to compare results across studies—or to replicate a specific study’s results with a different system. Second, the optimal treatment protocol (number of sessions, interval between sessions, injection technique) has not been established. Third, PRP results are not permanent—maintenance sessions are typically required every 3-6 months, making it an expensive long-term commitment.
Fourth, PRP has not been shown to be effective for advanced hair loss (Norwood grade V-VII) or in patients with extensive perifollicular fibrosis. Fifth, the procedure involves blood draws and scalp injections, which can cause discomfort, bruising, and, rarely, infection. Sixth, PRP is not FDA-approved for hair loss—its use is considered “off-label,” which means that insurance typically does not cover the cost.
Frequently Asked Questions
Is PRP worth the cost? The evidence supports modest improvement in early-stage AGA, but the cost (typically $1,500-4,500 for an initial course) and the need for ongoing maintenance sessions make it a significant investment. It may be most worthwhile for patients who cannot tolerate or choose not to use finasteride.
Can I combine PRP with minoxidil or finasteride? Yes. PRP is often used as an adjunct to standard treatments, and there is no theoretical reason why the combination would be harmful. Some studies suggest the combination produces better results than either approach alone.
How long do PRP results last? Maintenance sessions every 3-6 months are typically needed to sustain results. If PRP is discontinued, hair density generally returns to its pretreatment trajectory within 6-12 months.
Conclusion
PRP delivers a concentrated cocktail of growth factors (PDGF, VEGF, IGF-1, TGF-β, EGF, FGF) to the scalp, creating a pro-regenerative microenvironment that promotes anagen re-entry, perifollicular angiogenesis, and follicle cell proliferation. Clinical trials have shown modest but statistically significant improvements in hair density and diameter, with the best results in early-stage AGA. However, the lack of standardized preparation protocols, the variability in results across studies and patients, and the high cost of treatment are significant limitations. PRP is best viewed as an adjunctive treatment for early-stage AGA rather than a standalone therapy, and patients should have realistic expectations about the magnitude and duration of results.